Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Sequence-modified recombinant human factor VIIa

EU orphan designation number: EU/3/09/675   
Active ingredient: Sequence-modified recombinant human factor VIIa
Indication: Treatment of haemophilia A
Sponsor: Bayer Schering Pharma AG
D-13342 Berlin, Deutschland

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/10/2009 Centralised Orphan - Designation EMEA/OD/031/09 (2009)7920 of 09/10/2009